1stOncology™: Cancer Intelligence Service – Page 15746 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results

On January 29, 2018 Amgen (NASDAQ:AMGN) reported that it will report its fourth quarter and full year 2017 financial results on Thursday, Feb. 1, 2018, after the close of the U.S. financial markets (Press release, Amgen, JAN 29, 2018, View Source;p=RssLanding&cat=news&id=2328941 [SID1234523610]). The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen’s senior management team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

Investor Presentation dated January 29, 2018.

On January 29, 2018 KaloBios presented Investor Presentation (Presentation, KaloBios, JAN 29, 2018, View Source [SID1234523605]).

Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

On January 29, 2018 -Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, reported that three abstracts highlighting the Company’s Listeria-based immunotherapy in combination with antibody-based immunotherapies have been accepted for poster presentation at the upcoming 2018 Keystone Symposia on Cancer Immunotherapies: Combinations (C5) taking place March 23-27, 2018 at the Queen Elizabeth Fairmont in Montreal (Press release, Advaxis, JAN 29, 2018, View Source [SID1234523606]).

Title:

"Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model"

Poster Number:

2001
Session:

Poster Session 2
Date:

March 25, 2018
Presenter:

Rachelle E. Kosoff, Ph.D., Senior Scientist, Advaxis, Inc.

Title:

"Combination TIGIT blockade with Listeria-based immunotherapy enhances antigen-specific antitumor immunity"

Poster Number:

3015
Session:

Poster Session 2
Date:

March 25, 2018
Presenter:

Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc.

Title:

"Targeting of CCR8 induces antitumor activity as a monotherapy that is further enhanced in combination with a Listeria-based immunotherapy"

Poster Number:

3037
Session:

Poster Session 2
Date:

March 25, 2018
Presenter:

Daniel O. Villarreal, Ph.D., Principal Scientist, Advaxis, Inc.

"We are delighted to present these promising data before an audience of researchers and clinicians dedicated to elucidating the best possible combinations of targeted immunotherapies, to develop better treatments for patients with cancer. The data being presented highlight encouraging preclinical results, which show synergistic effects of a variety of antibody-based immunotherapies with our Lm Technology platform," said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis.

Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018

On January 29, 2018 Horizon Pharma plc (Nasdaq:HZNP) reported that its fourth-quarter and full-year 2017 financial results will be released on Wednesday, Feb. 28, 2018 (Press release, Horizon Pharma, JAN 29, 2018, View Source [SID1234523604]). Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast and replay may be accessed at View Source Please connect to the Company’s website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

Dr Sotirios G. Stergiopoulos appointed as Ipsen Chief Medical Officer

On January 29, 2018 Ipsen (Euronext: IPN; ADR: IPSEY) reported that Sotirios
G. Stergiopoulos, MD, has been appointed as Chief Medical Officer (Press release, Ipsen, JAN 29, 2018, View Source [SID1234523600]).

Dr Stergiopoulos joined Ipsen in January 2017 as Senior Vice President, Head of Global Medical Affairs (GMA) and will retain this
position in addition to the role as the new Chief Medical Officer within the company. Dr Stergiopoulos reports to Alexandre Lebeaut, MD, Executive Vice-President R&D and Chief Scientific Officer.

Dr Lebeaut commented, "Sotirios has extensive experience in directing global medical affairs
strategies and a strong expertise in oncology drug development that includes chemotherapy,
immunology drugs and targeted agents across various tumor indications. We are delighted to appoint
him to an expanded role through which he will make the voice of the patient heard at the highest levels
of the organization and represent the company externally as its primary medical representative."

Prior to joining Ipsen, Sotirios was Vice President, Head of Global Medical Affairs Oncology at Baxalta (now Shire, Cambridge, MA), Executive Medical Director Oncology US Medical Affairs at Celgene Corporation (Summit, NJ), Senior Global Brand Medical Director Oncology at Novartis Pharmaceuticals (East Hanover, NJ) and Director Medical Affairs Oncology at Bayer Healthcare
(Montville, NJ).

Dr. Stergiopoulos added, "I am delighted to take on this leading role at Ipsen. This is an exciting
time for Ipsen with significant growth and evolution. Together with our experienced leadership team,
I look forward to helping our company continue to bring innovative new medicines to our patients."

Dr. Stergiopoulos is a physician executive with significant experience in the Pharmaceutical/Biotech industry, especially in Oncology. He has held appointments as an Attending Physician and trainee in institutions such as Albert Einstein College of Medicine, Harvard Medical School and the National Institutes of Health. He holds a Masters in Biotechnology Enterprise and Entrepreneurship (MBEE) from The Johns Hopkins University and a Medical Degree from Poznan University of Medical
Sciences (Poland). Sotirios is a Fellow of the American College of Physicians, the New York Academy of Medicine as well as the Royal Society of Medicine (UK). He is also a Member of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) and of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper).
In October 2017 Dr. Stergiopoulos was appointed President of the Board of Governors for the Accreditation Council for Medical Affairs (ACMA); a body whose mission is to establish, certify, and maintain the competencies of qualified medical and scientific professionals who have a focus in Medical Affairs within the pharmaceutical & biotechnology industries.